Home > Products > CD3 & PD1
> Recombinant Anti-CD3 x Anti-PD1 Bispecific Antibody (scIgG)
Recombinant Anti-CD3 x Anti-PD1 Bispecific Antibody (scIgG) (CAT#: SCIGG-098)
Recombinant Anti-CD3 x Anti-PD1 Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-CD3 and anti-PD1 IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can retarget T cells to tumor cells. It is designed for the research of Esophageal cancer; Hodgkin lymphoma; Renal cell cancer (RCC); Mesothelioma; Head and neck squamous cell cancer (HNSCC); Anal cancer; Gastric cancer; Hepatocellular cancer; Nasopharyngeal cancer; Non-small cell lung cancer (NSCLC); Solid tumors therapy.
There are currently no customer reviews or questions for Recombinant Anti-CD3 x Anti-PD1 Bispecific Antibody (scIgG) (SCIGG-098). Click the button below to contact us or submit your feedback about this product.